Hoth Therapeutics Inc.
HOTH
We are a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. We are focused on developing (i) a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and (iii) a treatment and/or prevention for Alzheimer's or other ne…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$12M
▼ -52.3% YoY
Op. Margin
–
ROIC
-141.51%
▼ -67.2pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$11M
▼ -40.5% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$6M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with HOTH
Hoth Therapeutics (HOTH) in two numbers
Questions about Hoth Therapeutics
Does Hoth Therapeutics (HOTH) pay a dividend?
No. Hoth Therapeutics (HOTH) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 12 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in HOTH's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing HOTH
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.